Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line Bismuth-containing Seven-day Concomitant Quintuple Therapy for Helicobacter pylori Eradication
ChiCTR-OPC-16008659Phase 4Completed
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Aug 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esomeprazole, clarithromycin, amoxicillin, metronidazole and bismuth subcitrate in Helicobacter pylori infection, chronic gastritis and Peptic ulcer disease (PUD), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: eradication rate of Helicobacter pylori infection. Started Aug 2015; status: completed.
02
Drugs
esomeprazoleclarithromycinamoxicillinmetronidazolebismuth subcitrate
03
Conditions
Helicobacter pylori infectionchronic gastritisPeptic ulcer disease (PUD)
Beyond the preview
Go deeper on ChiCTR-OPC-16008659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16008659.